Skip to main content

AIM2 Antibody (10M5G5)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-27354

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2a Kappa Clone # 10M5G5

Concentration

0.5 mg/ml

Product Specifications

Immunogen

This antibody was raised against AIM2

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2a Kappa

Scientific Data Images for AIM2 Antibody (10M5G5)

Western Blot: AIM2 Antibody (10M5G5) [NBP2-27354]

Western Blot: AIM2 Antibody (10M5G5) [NBP2-27354]

Western Blot: AIM2 Antibody (10M5G5) [NBP2-27354] - Western blot analysis of Daudi lysate (35 ug per lane, RIPA buffer) using AIM2 antibody (NBP2-27354) at 0.1ug/ml. Band observed at ~38kDa. (Expected MW of 39.0kDa according to NP_004824.1).
Western Blot: AIM2 Antibody (10M5G5) [NBP2-27354]

Western Blot: AIM2 Antibody (10M5G5) [NBP2-27354]

Western Blot: AIM2 Antibody (10M5G5) [NBP2-27354] - Analysis using AIM2 antibody. Recombinant human AIM2 probed with AIM2 antibody at 2 ug/ml.

Applications for AIM2 Antibody (10M5G5)

Application
Recommended Usage

Western Blot

2-5ug/ml
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

0.2 ml PBS and 0.05% BSA

Preservative

0.05% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: AIM2

AIM2 (Absent in Melanoma-2) is an interferon-inducible cytosolic protein of the IFI20X/IFI16 family, which is essential for an effective innate immune response. It plays a key role in the defence against bacterial and viral DNA. AIM2 is essential for inflammasome activation in response to Francisella tularensis, vaccinia virus and Listeria monocytogenes (Fernandes-Alnemri T et al, 2009). It recognizes cytosolic dsDNA and forms a Caspase-1 activating inflammasome with ASC (apoptosis-associated speck-like protein containing a CARD) protein (Jones JW et al, 2010). The C-terminal HIN domain binds double stranded DNA and acts as a cytosolic dsDNA sensor. The pyrin domain allows for the association with ASC and formation of the inflammasome. Formation of the AIM2 inflammsome leads to the processing and release of mature IL-1Beta and IL-18 and host cell death (Hornung V et al, 2009). AIM2 plays a role in tumorigenic reversion and may control cell proliferation. It may repress NF-kappaB transcriptional activity.AIM2 antigen is expressed in a wide variety of tumor types, including neuroectodermal tumors, as well as breast, ovarian and colon carcinomas. AIM2 induces the expression of invasion-associated genes such as VIM and MCAM, whereas downregulates ANXA10 and CDH1. AIM2 reduces breast cancer proliferation and mammary tumor growth and shows a high frequency of frameshift mutations in microsatellite unstable (MSI-H) gastric, endometrial and colorectal cancers.Defects in AIM2expression within immune cells contribute to increased susceptibility to lupus. AIM2 could be used as a tumor antigen target for monitoring vaccine trials or to develop antigen specific active immunotherapy for glioma patients. It may serve as a potential therapeutic gene for future development of AIM2-based gene therapy for human breast cancer (Liu G et al, 2004).

Long Name

Absent In Melanoma 2

Alternate Names

Gm1313, Ifi210, PYHIN4

Gene Symbol

AIM2

UniProt

Additional AIM2 Products

Product Documents for AIM2 Antibody (10M5G5)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for AIM2 Antibody (10M5G5)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...